RESEARCH ARTICLE

The O-Linked Glycome and Blood Group Antigens ABO on Mucin-Type Glycoproteins in Mucinous and Serous Epithelial Ovarian Tumors

Varvara Vitiazeva1*, Jayesh J. Kattla1, Sarah A. Flowers1, Sara K. Lindén1, Pushpa Premaratne1, Birgitta Weijdegård2, Karin Sundfeldt2, Niclas G. Karlsson1

1 Department of Medical Biochemistry, University of Gothenburg, Gothenburg, Sweden, 2 Department of Obstetrics and Gynecology, Institute of Clinical Sciences, Sahlgrenska Cancer Center, University of Gothenburg, Gothenburg, Sweden

* varvara.vitiazeva@gu.se

Abstract

Background

Mucins are heavily O-glycosylated proteins where the glycosylation has been shown to play an important role in cancer. Normal epithelial ovarian cells do not express secreted mucins, but their abnormal expression has previously been described in epithelial ovarian cancer and may relate to tumor formation and progression. The cyst fluids were shown to be a rich source for acidic glycoproteins. The study of these proteins can potentially lead to the identification of more effective biomarkers for ovarian cancer.

Methods

In this study, we analyzed the expression of the MUC5AC and the O-glycosylation of acidic glycoproteins secreted into ovarian cyst fluids. The samples were obtained from patients with serous and mucinous ovarian tumors of different stages (benign, borderline, malignant) and grades. The O-linked oligosaccharides were released and analyzed by negative-ion graphitized carbon Liquid Chromatography (LC) coupled to Electrospray Ionization tandem Mass Spectrometry (ESI-MSn). The LC-ESI-MSn of the oligosaccharides from ovarian cyst fluids displayed differences in expression of fucose containing structures such as blood group ABO antigens and Lewis-type epitopes.

Results

The obtained data showed that serous and mucinous benign adenomas, mucinous low malignant potential carcinomas (LMPs, borderline) and mucinous low-grade carcinomas have a high level of blood groups and Lewis type epitopes. In contrast, this type of fucosylated structures were low abundant in the high-grade mucinous carcinomas or in serous carcinomas. In addition, the ovarian tumors that showed a high level of expression of blood
group antigens also revealed a strong reactivity towards the MUC5AC antibody. To visualize the differences between serous and mucinous ovarian tumors based on the O-glycosylation, a hierarchical cluster analysis was performed using mass spectrometry average compositions (MSAC).

**Conclusion**

Mucinous benign and LMPs along with mucinous low-grade carcinomas appear to be different from serous and high-grade mucinous carcinomas based on their O-glycan profiles.

**Introduction**

Epithelial ovarian cancer (EOC) is the most lethal gynecological malignancy. This is mainly due to the fact that most of the EOC cases are diagnosed in late stages, when the 5-year survival rate is less than 37% [1]. Ovarian cancer is a relatively asymptomatic disease and as a result the detection of the EOC in earlier stages is a challenging task. Epithelial ovarian neoplasms are classified by histology into serous, mucinous, endometrioid, clear-cell and transitional or Brenner tumors [2].

Currently, Cancer Antigen (CA) 125 is the most used biomarker for ovarian cancer [3, 4]. A disadvantage of CA125 is its low sensitivity to ovarian carcinomas in stage I, where only 50% of patients have an increased level of CA125. Moreover, increased level of CA125 can also be detected in patients with endometriosis, pregnancy, uterine myomas, acute and chronic salpingitis and pelvic inflammatory disease [5, 6]. Of even greater concern is that CA125 and the more recently approved biomarker human epididymis 4 (HE4) [7] have limited diagnostic and prognostic value with the second most common type of EOC, mucinous ovarian cancer. Hence, mucinous ovarian tumors have a different biomolecular background that needs to be explored in order to improve diagnostics and treatment.

Nonetheless, CA125 is currently the best known biomarker for ovarian cancer, although over the last decade, several studies have been done in an attempt to find markers that can complement, improve or replace CA125 [7–10].

CA125 was identified as the transmembrane mucin MUC16 at the beginning of this century. As described in the literature, different types of epithelial cancer cells express different types of mucin glycoproteins on their surfaces [11–13]. Hence, it could be hypothesized that understanding differential mucin expression may lead to the identification of more effective biomarkers for the detection of various ovarian cancers and for following treatment progression.

Up to date, twenty one mucins are known. They can be subdivided into two groups: secreted mucins such as MUC2, MUC5AC, MUC5B, MUC6 and membrane bound mucins such as MUC1 and MUC16 [14] that could also be shed from the plasma membrane. Mucins are highly glycosylated high-molecular mass proteins expressed by epithelial cells. The glycosylation can contribute up to, or even greater than 80% of the total molecular weight of glycoproteins. These mucin-type glycoproteins are predominantly decorated by O-linked and to lower extent also by N-linked oligosaccharides.

O-glycosylation is initiated by the attachment of GalNAc to serine or threonine residues of the apomucin protein by a family of GalNAc polypeptide transferases [15, 16]. Further extension by Galβ1- or GlcNAcβ1- at the O-3 position and/or by GlcNAcβ1- at the O-6 position followed by elongation by type 1/ type 2 (Galβ1→3/4GlcNAcβ1→) units are carried out by a
series of Gal and GlcNAc transferases. Termination by sialyl- and fucose transferases generate epitopes such as sialyl Lewis a/x, blood group antigens A, B, O/H and Lewis a/b and Lewis x/y-type epitopes (Table 1) [15, 17]. Altered mucin glycosylation due to regulation of one or more of the glycosyltransferases together with ectopic expression of mucin-type glycoproteins is a hallmark of epithelial cancer [18–20]. A combination of both glycosylation and mucin expression may provide an alternative pathway to differentiate between ovarian cancer types.

We have previously shown that ascites fluid from serous ovarian cancer contains highly sialylated and sulfated mucin-type molecules [21]. In this report, we move closer to the site of cancer by studying the O-linked oligosaccharides from acidic glycoproteins secreted into cyst fluids by mass spectrometry. The objective was to identify differences in mucin expression and glycosylation between mucinous and serous type ovarian cancer of various stages and grades in order to provide a pathway, which could lead to the discovery of an effective biomarker for mucinous ovarian cancer.

Materials and Methods

Clinical samples

Ovarian cyst fluids (n = 19) and tumor tissue (n = 16) from women with ovarian tumors of mucinous and serous histology were chosen from our ovarian tumor biobank (Table 2). Patients were diagnosed by transvaginal sonography or computed tomography and admitted for surgical removal of the cyst by gynecologic oncology surgeons at Sahlgrenska University Hospital, Gothenburg, Sweden. Blood samples were taken after anesthesia but before surgery, and ovarian cyst fluids were collected after removal of the cyst from the abdomen. All samples were immediately put at 4°C for 15–30 min, centrifuged, and aliquoted into eppendorf tubes. The fluids were transferred to −80°C, 30–60 min after collection.

Sample characteristics

All tumors were examined by an experienced pathologist for diagnosis, histology, and grade (Table 2). The tumors were staged (I-IV) according to the International Federation of Gynecology and Obstetrics (FIGO) 2014 standards. CA125 was measured in blood and cyst fluid samples from all patients with ovarian disease using ELISA-CA125 (Cisbio Bioassays, Codolet, France) according to the manufacturer’s instructions.

Table 1. Examples of oligosaccharide epitopes expressed by mucin-type glycoproteins.

| Epitope     | Structure                                      |
|-------------|------------------------------------------------|
| Core 1      | Galβ1→3GalNAcα1→                              |
| Core 2      | Galβ1→3(GlcNAcβ1→6)GalNAcα1→                  |
| Core 3      | GlcNAcβ1→3GalNAcα1→                           |
| Blood group O/H | Fucα1→2Galβ1→                                |
| Blood group A | GalNAcα1→3(Fucα1→2)Galβ1→                    |
| Blood group B | Galα1→3(Fucα1→2)Galβ1→                      |
| Lewis a     | Galβ1→3(Fucα1→4)GlcNAcβ1→                     |
| Lewis x     | Galβ1→4(Fucα1→3)GlcNAcβ1→                     |
| Lewis b     | Fucα1→2Galβ1→3(Fucα1→4)GlcNAcβ1→             |
| Lewis y     | Fucα1→2Galβ1→4(Fucα1→3)GlcNAcβ1→             |

doi:10.1371/journal.pone.0130197.t001
Table 2. Clinical and biochemical characteristics of ovarian cyst fluid and tissue samples obtained from patients with mucinous and serous ovarian tumors.

| Sample Name | Blood group | Blood group Antigens | Patohistology | Plasma CA125 U/mL | Immunohistochemistry on tissue slides | Secretor status |
|-------------|-------------|---------------------|---------------|-------------------|--------------------------------------|----------------|
| 1M-Ba,b B   | 44         | Mucinous cystadenoma| Benign NR     | 17                | 3 3 cytoplasmic 1 3 membranous 3 3 cytoplasmic positive |
| 2M-Ba A     | 54         | Mucinous cystadenoma| Benign NR     | 11.8              | - - - - - - - negative |
| 3M-LMP-IAa B| 43         | Mucinous cystadenoma| LMP IA 57.7   | 1 2 cytoplasmic 0 0 NR 2 1(2) cytoplasmic negative |
| 4M-LMP-IAa A| 57         | Mucinous cystadenoma| LMP IA 8.4    | 1 2 cytoplasmic 1 2 membranous/cytoplasmic 3 3 cytoplasmic - |
| 5M-LMP-IAa A| 41         | Mucinous cystadenoma| LMP IA 22.8   | 3 3 cytoplasmic 1 1 cytoplasmic/membranous 3 3 cytoplasmic - |
| 6M-LMP-III A| 60         | Mucinous cystadenoma| LMP IIIA 106.4| - - - - - - - negative |
| 7M-Low-IAa,b A| 36   | Mucinous + endometroid adenocarcinoma| Low IA 49.7 | 3 3 cytoplasmic 0 0 NR 3 2(3) cytoplasmic positive |
| 8M-Low-IAa A | 57       | Mucinous cystadenocarcinoma| Low IA 11.7 | 3 3 cytoplasmic 0 0 NR 3 2(3) cytoplasmic positive |
| 9M-Low-IAa,b A| 53   | Mucinous adenocarcinoma + mullerian mix| Low IIIC 14.6| - - - - - - - - - |
| 10M-Low-IV O | 69       | Mucinous adenocarcinoma| Low IV 195.5 | 2 2 cytoplasmic 3 2 cytoplasmic - |
| 11M-High-IBa A| 56   | Mucinous adenocarcinoma| High IB 33.8 | 0 0 NR 1 3 membranous/cytoplasmic 3 2(3) cytoplasmic negative |
| 12M-High-IBa A| 68   | Mucinous adenocarcinoma| High IA 20.7 | 2 1,2,3 cytoplasmic 3 3 cytoplasmic/membranous 3 2(3) cytoplasmic positive |
| 13S-Low-IAa,b O | 45 | Serous papillary cystadenocarcinoma| Benign NR | 18 0 0 NR 3 2 membranous/cytoplasmic 3 2 cytoplasmic - |
| 14S-Low-IAa O | 59      | Serous papillary cystadenoma| Benign NR 7.9| - - - - - - - - - |
| 15S-LMP-III O | 82     | Serous papillary cystadenoma| LMP IA 61.6 | 0 0 NR 3 3 membranous/cytoplasmic 3 2 cytoplasmic - |
| 16S-LMP-III O | 44     | Serous papillary cystadenoma| LMP IIIC 184.6| 1 2 cytoplasmic 3 2 membranous 3 2 cytoplasmic - |
| 17S-LMP-III O | 40     | Serous papillary cystadenoma| LMP IA 255.8| - - - - - - - - - |
| 18S-Low-IIICb O| 45  | Serous papillary cystadenocarcinoma| Low IA 21.3 | - - - - - - - - - |
| 19S-Low-IVb A| 84      | Serous papillary cystadenocarcinoma| Low III 2314.6| - - - 3 3 membranous 3 2(1) cytoplasmic - |
| 20S-Low-IIICb A| 64   | Serous papillary cystadenocarcinoma| High III 2005.7| 0 0 NR 3 3 membranous/cytoplasmic 3 2 cytoplasmic - |
| 21S-Low-IIICb A| 73   | Serous papillary adenocarcinoma| High IV 6547.7| - - - - - - - - - |
| 22S-Low-IIICb A| 85  | Serous papillary adenocarcinoma| High III 121.6| - - - - - - - - - |
| 23S-High-IAa A| 54     | Serous papillary adenocarcinoma| High IA 129.8| - - - - - - - - - |

a The O-linked oligosaccharides from cyst fluid were analyzed by LC-ESI-MS<sup>+</sup>.
b The cyst fluid sample was analyzed by proteomic analysis.
NR- means not relevant
-- means not determined
doi:10.1371/journal.pone.0130197.t002
Ethics Statement

The study was approved by the local ethics committee at the University of Gothenburg, and each patient provided their informed written consent. Patient samples were collected, decoded and stored by dedicated staff. Ethics approval was obtained for the collection and biobanking of cystic fluid, ascites, ovarian tissue and plasma (Dnr: S348-02 and S445-08).

Acidic glycoproteins

Ovarian cyst fluid samples (~0.5 mL) were diluted (10 times) with starting buffer (250 mM sodium chloride in 20 mM Tris/10 mM ethylenediaminetetraacetic acid (pH 7.5) and injected on a diethylaminoethyl fast flow (1 mL) column (GE Healthcare, Uppsala, Sweden). After loading (10 min), the columns were washed with 10 mL of the starting buffer and the retarded fraction was collected (10 mL) by increasing the sodium chloride concentration to 1.0 M. Proteins were precipitated with ethanol (80% final concentration) at −20°C for 12 h. The obtained dried glycoproteins were resuspended in 3.5 M urea, dot blotted onto polyvinylidene fluoride (PVDF) membranes and stained with Direct Blue 71.

Release of O-linked oligosaccharides

O-Linked oligosaccharides were released from PVDF membranes by reductive β-elimination as previously described [22] and analyzed by LC-ESI-MS using a 10 cm × 250 μm I.D. column, packed in house with 5 μm porous graphitized carbon particles (Thermo Scientific, Waltham, MA) and a linear gradient of 0 to 40% acetonitrile solution in water, containing 10 mM ammonium bicarbonate over 40 min with a static split flow rate of 250 μl/min bringing down the on-column flow rate to 5–10 μl/min.

Mass spectrometric data was collected in negative ion mode using a Thermo Scientific LTQ ion trap mass spectrometer (San Jose, CA) with an electrospray voltage of 3.5 kV, capillary voltage of −33.0 V, and capillary temperature of 300°C. The data were manually interpreted as described [23]. Structural assignment was performed by the comparison of MS2 spectra from isolated chromatographic peaks to structures identified in the UniCarb-DB glycomic database [24].

LC-ESI-MS<sup>n</sup> Identification of high-molecular-weight acidic glycoproteins

The acidic fraction from cyst fluids were reduced (50 mM dithiothreitol, RT, 2 hr) and alkylated (125 mM iodoacetamide, 30 min, RT in dark) before the reaction was stopped (125 mM dithiothreitol). Samples (25 μl) were separated using NuPAGE 3–8% Tris-acetate gels (Life Technologies) and stained with Imperial Coomassie protein stain (Thermo Scientific).

Coomassie stained gel bands and gel areas of interest were excised, destained (50 mM ammonium bicarbonate), dried and digested with 300 ng sequencing-grade Lys-C (50 mM ammonium bicarbonate, 4 h, 37°C) followed by 500 ng trypsin (Promega, Madison, WI, USA) (overnight, 37°C). Samples were dried and resuspended in 50 mM ammonium bicarbonate with 0.2% formic acid for LC-ESI-MS<sup>n</sup> analysis. Data was searched against the UniProt human protein database using X! Tandem with the Orbitrap predefined method including reversed sequences [25].

All tryptic peptides were analyzed by nano-flow reverse-phase LC-electrospray ionization LC-ESI-MS<sup>n</sup> using an LTQ-Orbitrap XL mass spectrometer (Thermo Scientific) as previously described [26]. Briefly, 3 μL of each digest was injected into a precolumn (4 cm × 100 μm inner diameter) and analytical column (20 cm × 50 μm inner diameter) packed with ReproSil-Pur C18-AQ 3 μm resin (Dalco Chromtech, Stockholm, Sweden). A split flow rate of 100 nL/
min was used. A two-step gradient was used as follows: 0–40% solvent B (70% acetonitrile with 0.2% formic acid) in 50 min, 40–100% solvent B in a further 20 minutes. After washing with 100% B, the column was equilibrated with 100% solvent A (aqueous 0.2% formic acid). Full MS scans were obtained in the Orbitrap at m/z 400–2000, 2 microscans, maximum ion injection time 500 ms, and a target value of 500,000, using the lock mass feature for internal calibration (m/z 445.1200). Six data dependent MS² scans were acquired in the ion trap using collision induced dissociation fragmentation and normalized collision energy of 30, activation time of 30 and activation energy of 0.250. The RAW file format were converted to mzXML using the MassMatrix conversion tool [27].

Secretor status

Secretor status was evaluated by sequencing the coding exon of FUT2.

Genomic DNA was extracted from ovarian tissue cells in Clinical Molecular Pathology, Sahlgrenska University Hospital. The FUT2 exon was amplified with PCR and sequenced in the Gene analysis, Clinical Chemistry, Sahlgrenska University Hospital using primer: FUT2-sense: 5’—CCC CAT CTT CAG AAT CAC C—3’ and FUT2-antisense: 5’—TAC TGG TGA CCA CGA AGA TG—3’ (Invitrogen Life Technologies, Thermo Fisher, Waltham, MA). Individual’s secretor genotype was defined as non-secretor, when the in FUT2 c.385 A > T (p.Ile129Phe), c.428G > A (p.Trp143stop) and c.571 C > T (p.Arg191stop).

Immunohistochemical analysis

Ovarian tumor tissues were processed for immunohistochemical staining according to the manufacturer’s instructions (Vector Laboratories, Burlingame, CA, Thermo Scientific).

Paraformaldehyde-fixed paraffin-embedded 4-μm sections of ovarian tissue were deparaffinized, rehydrated and subjected to an antigen retrieval procedure using antigen unmasking solution (Vector Laboratories). The tissue sections were incubated with mouse monoclonal antibody: Anti-MUC5AC [clone 45M1; 1:400; Abcam], Anti-MUC16 [clone X75; 1:2000; Abcam] and biotinylated Ulex Europaeus Agglutinin I (UEA I) (1:400; Vector Laboratories). Negative controls underwent a similar staining procedure, with the exclusion of primary antibody or lectin. After incubation with secondary antibodies or streptavidin, immunodetection was performed using UltraVision Quanto Detection System HRP (Thermo Scientific).

Antigen expression levels were semiquantified on the basis of the proportion of cells of the same type cells staining positive. Positively stained cells were evaluated by the brown color, its intensity and spread in the tissues using a light microscope Nikon Eclipse 90i (Nikon, Tokyo, Japan) at x200 magnification. The proportion of positive tumor cells were scored from 0–3 (None = 0, <1/3 = 1, 1/3-2/3 = 2, >2/3 = 3). The intensity of staining was scored from 0–3 (None = 0, Weak = 1, Moderate = 2, Strong = 3). The scoring of staining intensity was performed in a blinded manner. Scores represent the average score of 0.5 cm² tumor. Porcine gastric tissues were used as positive control for MUC5AC and UEA I.

Mass Spectrometry Compositional analysis

Mass spectrometry average compositions (MSAC) of oligosaccharides were calculated as described previously [28]. Briefly, all structures identified by LC-ESI-MSⁿ and presented in S1 and S2 Tables were reduced to monosaccharide compositions (the number of hexose (Hex), N-acetylatedhexosamine (HexNAc), fucose (Fuc), sialic acid (NeuAc) residues and sulfate groups (S) in the structure). The monosaccharide compositions were multiplied by percentage intensity for each structure and summed over the entire sample giving the MSAC values.
Statistical analysis

Due to the limited number of samples, our data did not follow a typical Gaussian distribution. The separation test between mucinous and serous ovarian cyst fluid samples was evaluated by descriptive statistics such as receiver operation characteristic (ROC) curves. The area under the ROC (AUC) curves were constructed, compared and used for cluster analysis. Heat plots were constructed as described previously [28]. All statistical analyses were performed using the R package, version 3.0.2.

Results

The O-glycome from ovarian cyst fluid differs between serous and mucinous ovarian cancer by the expression of blood group antigens

Alterations in sialylation and sulfation of O-linked oligosaccharides have been described as a consequence of malignancy [18]. In addition, the histological differences between serous and mucinous epithelial ovarian cancer makes it likely that there are not only malignant differences in the O-glycosylation but also differences depending on the sub-type of cancer. These variations may not only be seen in the tissue but could also be reflected in the adjacent cyst fluids. To investigate these potential differences, ovarian cyst fluid and/or tumor tissues were collected from patients with benign and malignant serous (n = 11) and mucinous (n = 13) epithelial ovarian tumors of different stages and grades (Table 2). The O-glycomes of highly acidic glycoproteins from eight of the serous and eleven of the mucinous ovarian cyst fluids were studied by analyzing released O-linked oligosaccharides by LC-ESI-MSn (Table 2, S1 and S2 Tables).

The full scan spectra of O-linked oligosaccharides from the analyzed malignant serous (six samples of different grades and stages), but also four of the analyzed mucinous samples (one low malignant potential (LMP), three malignant high-grade carcinomas) cyst fluid samples were dominated by mono- and di-sialylated core 1 (Galβ1-3GalNAc-ol) and core 2 (Galβ1-3Galβ1-4GlcNAcβ1–6GalNAc-ol) (Fig 1B–1D). In contrast, the MS spectra of released oligosaccharides from the seven mucinous (two benign, two LMPs (borderline-type), three low-grade malignant) together with two serous benign samples were found to be much more heterogeneous (Fig 1A). Investigation of full scan and MS2 spectra showed that the O-linked oligosaccharides of these samples contained highly abundant structures containing fucose (Fuc). This indicated the presence of blood group ABO antigens and/or Lewis-type epitopes. MS2 fragmentation of the highly abundant fucose containing oligosaccharides from mucinous ovarian tumors demonstrated terminal sequences predominantly corresponding to blood group A (Fucα1-2(GalNAcα1–3)Galβ1-) blood group B (Fucα1-2(Galα1–1-3)Galβ1-), and blood group O (Fucα1-2Galβ1-, also known as blood group H) epitopes. The mass spectrometric assignment that many of the structures were indeed blood group antigens (S1 Table) was strengthened by the match between the identified structures and the individual patients recorded blood group ABO status (Table 2).

The secretor (Se) gene and the expression of blood group antigens in mucinous cyst fluid

With the high expression of blood group antigens appearing to be the main differentiator between the mucinous and serous O-glycomes, our attention was drawn to mucinous patients’ cyst fluid that did not fit to this pattern (Fig 2A). It is known that about 20% of the population has a non-functional Fucα1–2 transferase FUT2 (Se) gene, which is responsible for making the blood group O/H in secretion. FUT2 is analogous to Fucα1–2 transferase FUT1 and makes the same blood group O/H structure in the hemic system [29]. Hence, it was hypothesized that the
low level of blood group antigens expression in mucinous ovarian cyst fluid could be due to the non-secretor status of the patients. For validation of this particular hypothesis, nine mucinous ovarian tumor samples were selected and subjected to pyrosequencing analysis of FUT2 gene (Table 2). The analysis showed that 6 patients were homozygote or heterozygote carrying at least one copy of the most common functional FUT2 allele with A at position 129, G at position 143 and C at position 191. The additional 3 were homozygotes for A at position 143, identifying them as non-secretors. LC-ESI-MSn experiments on O-glycans indicated that, two of these patients have low expression of blood group antigens in their cyst fluids (3M-LMP-IA, 11M-High-IIB; Fig 2A). The third one (6M-LMP-IIIA; Table 2), where the corresponding cyst fluid was not available, was found by immunohistochemistry to have very low expression of fucosylated structures on the epithelial surface of the tumor tissue.

However, the non-functional Sf gene could only partly explain the low amount of blood group antigens in cyst fluids in some mucinous sample. The data in Figs 1 and 2A also suggested that high-grade mucinous ovarian cancer cells express less blood group antigens compared to low-grade carcinoma, LMP and benign adenoma since the general fucosylation levels of O-glycans in samples were reduced. Furthermore, the analysis of O-glycosylation indicated...
that the high-grade mucinous glycosylation profile was similar to that from the malignant serous samples.

It should also be mentioned that the low expression of fucose found in four of the mucinous and most of the serous samples did not mean that these samples were devoid of blood group antigens. For instance, the full scan spectrum of serous papillary low grade cystadenocarcinoma
stage IIIC sample (20S-Low-IIIC, S2 Table) showed low intense signal of [M-H]$^-$ ions at m/z 1348 and 1057 indicating the expression of Fucα1-2(Galα1–3)Galβ1- epitope in agreement with blood group B of the patient (S2 Table).

**Fucosylation on epithelial ovarian cancer tissue**

Since ovarian cyst fluids showed pronounced differences in O-glycosylation of mucin type glycoproteins, we were also interested in how the fucosylation (blood group ABO and/or Lewis type structures) found in mucinous cyst fluids were reflected in the corresponding cancer tissue. This was investigated by analyzing the reactivity of epithelial tissue to lectin, *Ulex europeus* Agglutinin I, recognizing fucosylated oligosaccharides (Fig 3; Table 2).

Cytoplasmic staining against fucose was noted in all examined ovarian tumors. However, in general, the serous tumors showed lower levels of expression of fucosylated structures compared to mucinous samples.

**MUC5AC is expressed in mucinous ovarian tumors**

In order to determine the type of mucin proteins secreted into cyst fluids by the cancer tissue, proteomic analyses of high-molecular mass glycoproteins from acidic fractions were performed on a small sample set including mucinous and serous samples of benign cystadenoma, stage I and stage III adenocarcinomas. MUC5AC was detected in all mucinous samples and was not detected in any of the serous samples (Table 3). This observation was further substantiated by detection of MUC5AC in the tissue staining, where cytoplasmic staining was seen in the majority of mucinous ovarian tumors (Fig 3; Table 2). Lack of MUC5AC staining was observed for two high-grade mucinous adenocarcinomas, indicating a loss or lowered expression of MUC5AC in cancer cells with high differentiated grade. This observation is consistent with our LC-MS$^n$ data detecting a relative reduction in O-linked oligosaccharides from high-grade mucinous cyst fluid samples. This finding suggests a reduction in the amount of MUC5AC secreted into cyst fluid in these samples rather than a lower antibody binding due to alteration in O-glycosylation.

With the exception of one LMP tumor with low reactivity, all serous ovarian tumors showed an absence of immunoreactivity toward MUC5AC antibodies (Table 2). The tissue staining of MUC5AC and the fucose binding lectin staining were found to coincide in the mucinous ovarian tumor tissue indicating that the two molecules were secreted by the same cell and suggested that blood group antigens could be carried by MUC5AC in the tissue and in cyst fluid.

**MUC16 is poorly expressed by mucinous ovarian cancer cells**

Immunohistological staining with CA125/MUC16 antibody demonstrated the problem with utilizing this antigen for detection of mucinous ovarian cancer (Fig 3). All examined serous tumor tissues were MUC16 positive. In contrast, the level of staining of mucinous ovarian tumors varied, but tended to have a lower level of expression (Table 2). The CA125/MUC16 immunoreactivity was characterized predominantly by membranous staining but cytoplasmic staining was also present both in serous and mucinous samples. Two biopsies from two different mucinous ovarian carcinomas were positive for both MUC5AC and MUC16. However, the area expressing MUC16 did not express high levels of MUC5AC and vice versa (Fig 4). This observation suggested that mucinous ovarian tumors, expressing predominantly MUC5AC did not express, or expressed low levels of MUC16.
Fig 3. Tissue localization of α-fucose, MUC5AC (gel-forming mucin) and MUC16/CA125 (trans-membrane mucin) in benign, low-grade and high-grade serous and mucinous ovarian tumor cells. The figure shows the tissues from mucinous benign (1M-B), low-grade (7M-Low-IA), high-grade (13M-High-IB) as well as from serous benign (14S-B), low-grade (20S-Low-III), high-grade (21S-High-IIIC) tumors (Table 2). Tissues were stained with lectin (UEA I) against fucose, or mucin specific antibodies (anti-MUC5AC and anti-MUC16).

Table 3. Mucins identified by mass spectrometry in cyst fluid samples obtained from patients with serous and mucinous ovarian benign tumors and stage I, III EOC.

| Sample №/Name | Mucin Identified | MW kDa | Protein Expectation value (log(e)) | № of peptides identified | Link |
|---------------|-----------------|--------|------------------------------------|--------------------------|------|
| 1M-B          | Mucin-5AC (P98088) | 526.3  | -27.4                              | 5/30                     | http://human.thegpm.org/thegpm-cgi/plist.pl?path=/gpm/archive/GPM32100041892.xml |
| 7M-Low-IA     | Mucin-5AC (P98088) | 526.3  | -25.5                              | 32/186                   | http://human.thegpm.org/thegpm-cgi/plist.pl?path=/gpm/archive/GPM32100040512.xml |
| 9M-Low-IIIC   | Mucin-5AC (P98088) | 526.3  | -13.8                              | 3/4                      | http://human.thegpm.org/thegpm-cgi/plist.pl?path=/gpm/archive/GPM32100041769.xml |
| 14S-B         | Mucin-5B (Q9HC84)  | 590.1  | -58.5                              | 8/11                     | http://human.thegpm.org/thegpm-cgi/plist.pl?path=/gpm/archive/GPM32100040515.xml |
| 19S-Low-IA    | No mucin detected|        |                                    |                         |      |
| 23S-High-IIIC | Mucin-5B (Q9HC84)  | 590.1  | -7                                 | 1/1                      | http://human.thegpm.org/thegpm-cgi/plist.pl?path=/gpm/archive/GPM32100040535.xml |

Mw—Molecular weight of apoprotein obtained from protein database. 
Protein expectation value—log(e), the base 10 log of the expectation that the protein assignment was made at random. All identifications are of high confidence.

№ of peptides identified—the number of unique and total peptides used in the identification.
Sialylation and sulfation of cyst fluid oligosaccharides

Since the secretor status highly influenced the fucose expression by epithelial ovarian tumor cells, two other oligosaccharide moieties for termination, sialic acid and sulfate, were investigated. The objective was to see how their appearance was correlated with the blood group antigens.

The Fucα1–2 transferase (FUT2) is responsible for synthesis of the Fucα1-2Galβ1-epitope, which is the common structure for all ABO blood group antigens. However, the galactosylated precursor for FUT2 can also be elongated by α-(2,3)-sialyltransferase giving NeuAcα2-3Galβ1-terminal structure [30]. Hence, there could be a correlation between blood group expression and the level of sialylation of the O-glycome [31]. Sulfation, on the other hand, can terminate oligosaccharide elongation by the addition of a sulfate group to terminal non-reducing Gal, similar to the FUT2 fucosyltransferase and sialyl transferases.

Alternatively it can act on internal residues, preferentially on the O-6 position of GlcNAc residues [32].
The full scan spectra of the O-glycomes, illustrated that the expression of blood group antigens was not necessary in competition with the expression of sulfated glycans; the MS spectrum from one serous benign sample (15S-B) showed high abundant [M-H]\(^{-}\) ions at \(m/z\) 829, 975, 1121 and 1266 corresponding to sulfated oligosaccharides (Fig 5A). Furthermore, the MS\(^2\) spectrum of [M-H]\(^{-}\) ion at \(m/z\) 1121 showed that it also carried two blood group O/H epitopes. Fragment ions at \(m/z\) 975, 813 and 590 corresponding to consecutive losses of the monosaccharide units in Fuc\(\alpha\)1-2Gal\(\beta\)1-3GalNAc-ol indicated that this was a blood group O/H core 2 type structure. The fragment ions at \(m/z\) 444 and 505 indicated that the sulfate group was located on the GlcNAc linked to the GalNAc-ol (Fig 5B), and both branches were shown to be terminated by a blood group O/H type epitope at their non-reducing end. Hence, it can be suggested that the sulfation of the GlcNAc unit is biosynthetically independent of both blood group ABO and sialylation.

The average amount of sulfate groups in serous benign samples was approximately 15–16% (S1 Table). However, the amount of sulfation in the O-glycome from mucinous benign samples was only up to approximately 6%. Therefore, it can be speculated that sulfation would also provide complementary information about mucinous/serous differentiation (Fig 2C).

Serous epithelial ovarian cancer can be distinguished from mucinous low-grade ovarian cancer and benign mucinous and serous tumors

As Fig 2A highlights, the mass spectrometry average composition (MSAC) of the fucose residue (Fuc) appeared to be a good parameter for distinguishing the O-glycomes from serous and mucinous tumors. In order to validate this finding, nonparametric ROC analyses were performed for all MSAC parameters: Hex, HexNAc, Fuc, NeuAc and S (Fig 6). This analysis showed that Fuc, NeuAc and S are the most prominent parameters to distinguish the serous and mucinous samples (Fig 6) whereas AUC of Hex and HexNAc had less predictive value. Base on this, the heat plot was constructed using only Fuc, NeuAc and S (Fig 6A). The resulting plot shows the separation of the samples into three groups by hierarchical clustering. The analysis of these clusters confirmed our observation that low-grade, LMP and benign mucinous samples can be separated from all serous EOC samples, whereas, the serous benign samples form a separate group. However, as expected, one exception was observed. One mucinous LMP sample from a non-secretor patient did not follow this differentiation pattern (Fig 6; sample is marked by green color).

A statistical analysis of linear correlation coefficients between Fuc, NeuAc and S variables showed a strong correlation between Fuc and NeuAc (\(R = 0.89\)), possibly due to the biosynthetic competition between fucosylation and sialylation of O-linked oligosaccharides.

The heat plot using only two variables Fuc and NeuAc gave an equally good separation of all samples into three groups as by using three parameters (Fuc, NeuAc and S) (Fig 6B).

Discussion

In the present study we investigated the differences in O-glycosylation of acidic glycoproteins secreted into cyst fluids by serous and mucinous epithelial ovarian tumors by mass spectrometry. In addition, the variation of expression of secreted mucin-type glycoproteins was also analyzed by immunohistochemistry. Since epithelial ovarian tumors are commonly grown in cystic formations, cyst fluids are enriched with glycoproteins secreted by malignant epithelial cells [33]. Consequently, the analysis of cyst fluids could aid the study of cancer differentiation and progression leading to new ovarian cancer biomarkers in order to improve early detection and the survival rate.
Our immunohistochemistry results showed that mucinous ovarian tumor cells were associated with a high level of expression of gastric-type mucin MUC5AC (gel-forming mucin), whereas the serous ovarian tumor cells did not show any substantial staining with the MUC5AC antibody. These results were in agreement with a previous immunohistochemistry study showing that none of 37 analyzed serous ovarian tumors expressed MUC5AC on their surfaces [11]. Although in another study, Giuntoli et. al showed mRNA expression of MUC5AC in both mucinous and serous ovarian cancer tissues by Northern blotting analyses [12]. They also found that transformed, nonmalignant ovarian epithelial cell lines expressed both MUC5AC and MUC1 (membrane bound mucin) genes [12]. However, mucin expression and secretion are dynamic processes and direct correlation between mRNA level and the level of secreted protein is not always observed [34].

In the present study, MUC5AC was the only mucin-type glycoprotein that was identified by proteomic analyses of acidic high-molecular weight proteins obtained from three mucinous ovarian cyst fluids (benign cystadenoma, low-grade stage I and low-grade stage III adenocarcinomas). Although our data does not exclude the presence of other mucins in cyst fluids, it can be suggested that MUC5AC is the most abundant mucin-type glycoprotein in mucinous cyst fluids.
Fig 6. Hierarchical cluster analyses of O-glycans from serous and mucinous ovarian tumors. The clustering based on three variables Fuc, NeuAc and S (A) and also only the two variables NeuAc and S (B). The variables were evaluated using ROC AUC (C). The dendrograms (A, B) identify mucinous benign, LMPs and low-grade ovarian tumors as a distinct group (the group is marked by red color) separate from serous and high grade mucinous samples (the group marked in black). The exception is the LMP mucinous cyst fluid sample obtained from a non-secretor patient (green color). A separate cluster is generated by the two serous benign samples (violet color).

doi:10.1371/journal.pone.0130197.g006
fluids. The immunohistochemical staining showed some interesting features pointing to differentiation in expression of MUC5AC according to tumor cell differentiation grade. The expression of MUC5AC in the high-grade mucinous tumor cells seemed to be lower compared to benign, LMP and low-grade mucinous adenocarcinomas.

Consistent with previous observations [5, 10, 35], mucinous ovarian tumors in our study did not show a high level of expression of CA125/MUC16 neither on the tissue nor in the blood. Serous ovarian carcinomas with late stages III and IV displayed the highest level of CA125 in plasma ($^{21}$S-High-IIIC—2005.7U/ml, $^{22}$S-High-IV—6547.7U/ml) whereas the level of CA125 in plasma from mucinous ovarian carcinomas at stages III and IV were much lower ($^{8}$M-LowIIIC-141.6U/ml, $^{10}$M-Low-IV-195.57U/ml).

The present data indicated that serous and mucinous benign adenomas, mucinous LMP adenomas and mucinous low-grade carcinomas have a high level of fucosylation due to blood groups and Lewis-type epitopes, which were less abundant in the high-grade mucinous carcinomas and in all serous carcinomas. Our results suggested that the expression of fucosylated epitopes in mucinous tumors could be associated with differentiation grade. Welchinger et al did not find a significant difference in survival among patients depending on reactivity of cancer tissue to antibody against blood groups antigens [36]. However, the majority of patients in that study had advanced diseases (stage III and IV) with differentiation grade 2 and grade 3 (high-grade differentiation). These data are consistent with our study that indicated the low expression of fucosylated glycoforms in all serous and high-grade mucinous carcinomas.

Expression of several gel-forming mucins has been described for mucinous ovarian tumors such as MUC2, MUC5AC and MUC5B [11, 12, 37–40]. In our study, the ovarian tumors, which showed a high level of expression of blood group antigens in cyst fluid glycoproteins, also revealed a strong reactivity towards the MUC5AC antibody. Thereby, the expression of fucosylated O-linked oligosaccharides could be related to MUC5AC expression. The O-linked glycomes of acidic glycoproteins from cyst fluids were found to be similar to oligosaccharide structures from a previously defined O-glycome of gastric mucins MUC5AC and MUC6, which were isolated from gastric tissues of healthy humans [41]. However, the O-glycome from mucins described in that study, did not reveal any detectible level of sulfated O-glycans, while the sulfation level in the mucinous O-glycome analyzed in our study was found to be between 0.3% and 6% (S1 and S2 Tables).

The LC-ESI-MS profiles of O-linked oligosaccharides derived from cyst fluids of serous ovarian and high-grade mucinous EOC indicated very low expression of fucosylated epitopes. The cyst fluid O-linked oligosaccharides resembled O-linked oligosaccharides obtained from ovarian cancer ascites with its high level of sulfation and sialylation [21], and indicated a direct link between ascites and cystic fluid O-linked glycosylation. Except for the sulfation level, the O-glycome from ovarian cancer ascites as well as the O-linked oligosaccharides from cyst fluids from all serous and high-grade mucinous EOC were found to be similar to O-linked oligosaccharides from glycoproteins present in human plasma, which predominantly contain the short mono- and di-sialylated core 1 and core 2 structures [42]. The proteomic study of ovarian cyst fluids also showed their high resemblance to serum [33]. This indicated that O-glycomes from serous and high-grade mucinous EOC may have a substantial contribution from surrounding plasma.

Interestingly, the highest level of sulfation was found in the serous benign cystadenoma. Generally, the sulfation level of O-glycome from serous carcinoma samples seem to be slightly higher than in highly fucosylated O-linked oligosaccharides.

The difference in O-glycosylation between mucinous low-grade and high-grade carcinomas could also be associated with alteration in glycosylation during cancer progression. In the last decade, quite a number of reports were published about aberrant glycosylation and its relation
to epithelial cancer progression [30, 43]. For instance, the loss of expression of blood groups antigens has been observed in different types of cancer, such as a lung and breast cancer [44, 45]. However, epithelial cells such as colorectal epithelial cells that normally do not express ABO antigens on their surfaces show their expression in tumor formations [46, 47]. Pendu et al. proposed a working hypothesis that explains alterations in expression of blood groups antigens in epithelial cancers [30]. Briefly, they suggested that in the early stages of cancer, ABO antigens and Leewis b/y epitopes play an important role in epithelial cell resistance to apoptosis. This could explain their presence on epithelial cell surfaces at the initial stages of cancerogenosis even when they are not normally expressed. However, the loss of blood groups ABO at later stages increases cell motility and leads to metastasis [30].

Previously, glycan epitopes expressed by epithelial ovarian cancer cells were mostly studied by immunohistochemical analyses using monoclonal antibodies detecting Lewis-type structures (Le\(^a\), Le\(^b\), Sialyl-Le\(^a\) (sLe\(^a\)), Tn and STn and monoclonal antibodies against blood group antigens A,B and O/H [36, 48, 49]. In these studies, the high expression of the Le\(^b\) epitope was described for serous ovarian tumors, however, mucinous ovarian tumors were shown to react strongly to sLe\(^a\) antibody. Our LC-ESI-MS\(^n\) data of O-linked oligosaccharides derived from acidic glycoproteins secreted into ovarian cyst fluids showed that Le\(^b\) type epitopes were not present in the low molecular structures identified in this report. However monosaccharide compositions of larger detected structures did not exclude the possibility of Le\(^b\) epitopes among the low abundance high-molecular mass glycans (S2 Table). The presence of Le\(^b\) has also been shown to correlate with the expression of membrane-bound MUC1 and MUC16 mucins [49] as well as with expression of HE4 (Human Epididymis Protein 4) [50], which may explain the low abundance Le\(^b\) epitopes in O-linked oligosaccharides from secreted mucin-type glycoproteins.

Traditionally, epithelial ovarian tumors with different histologic sub-type and grade have been considered and treated as a single disease. However, the last published investigations have shown that they differ not only histologically, but also by gene and molecular expression, as well having a different clinical course and response to treatment [51–53].

Historically the treatment of cancer depends on the primary site, but it was suggested that treatments should be more dependent on the molecular characteristics of the tumor than on the organ of origin [54, 55]. Thus, to visualize the differences between glycosylation of ovarian cyst fluids, a hierarchical cluster analysis was performed as described by Hayes et al. [28]. Hierarchical clustering using three parameters (Fuc, NeuAc and S) or only two parameters (NeuAc and S) provided a differentiation of the samples that could be partly understood based on the assessment of grade and type but also provided additional suggestion for further stratification of the patients. One piece of clinical information that appeared to be important for the accuracy of predicting the mucinous ovarian cancer type based on the O-glycome from cystic fluid was the secretor status. This suggests that personalized diagnostics may be as important as personalized therapy.

In conclusion, the mucinous epithelial ovarian tumors can be distinguished from serous tumors by O-glycosylation profiles of mucin-type glycoproteins secreted into cyst fluids. Fucosylation as well as sialylation together with sulfation of O-glycans are important characteristics to differentiate the type of tumors. The presence of mucin MUC5AC in plasma has been reported for one epithelial cancer, cholangiocarcinoma [56].

Our next steps in the evaluation of mucins as a source for the new biomarkers for mucinous epithelial ovarian cancer will involve the development of serum assays specific to MUC5AC. The detailed study of MUC5AC O-glycosylation changes during mucinous ovarian cancer progression could lead to the development of assays recognizing both the apoprotein component and specific glycans of MUC5AC. For serous ovarian carcinomas a similar approach may also
be possible to correlate specific O-glycan epitopes with the expression of MUC16/CA125 in order to improve the diagnostic value of this marker.

Supporting Information

S1 Table. LC-ESI-MS\textsuperscript{n} data on O-linked oligosaccharides obtained from mucinous ovarian tumor cyst fluids.
(XLSX)

S2 Table. LC-ESI-MS\textsuperscript{n} data on O-linked oligosaccharides obtained from mucinous ovarian tumor cyst fluids.
(XLSX)

Acknowledgments

We acknowledge the Clinical Molecular Pathology and Gene analysis groups at Sahlgrenska University Hospital for purification and analyses of FUT\textsubscript{2} genes and Dr. Szilard Nemes for his kind consultation in statistical questions.

Author Contributions

Conceived and designed the experiments: VV JJK SKL KS NGK. Performed the experiments: VV JJK SAF PP BW. Analyzed the data: VV SAF KS NGK. Contributed reagents/materials/analysis tools: KS. Wrote the paper: VV SAF SKL KS NGK.

References

1. Holschneider CH, Berek JS. Ovarian cancer: epidemiology, biology, and prognostic factors. Semin Surg Oncol. 2000; 19(1): 3–10. PMID: 10883018
2. Dallenbach-Hellweg G. On the histogenesis and morphology of ovarian carcinomas. J Cancer Res Clin Oncol. 1984; 107(2): 71–80. PMID: 6715398
3. Meyer T, Rustin GJ. Role of tumour markers in monitoring epithelial ovarian cancer. Br J Cancer. 2000; 82(9): 1535–8. PMID: 10789720
4. Altaras MM, Goldberg GL, Levin W, Bloch B, Darge L, Smith JA. The role of cancer antigen 125 (CA 125) in the management of ovarian epithelial carcinomas. Gynecol Oncol. 1988; 30(1): 26–34. PMID: 2452770
5. Jacobs I, Bast RC Jr. The CA 125 tumour-associated antigen: a review of the literature. Hum Reprod. 1989; 4(1): 1–12. PMID: 2651469
6. Medeiros LR, Rosa DD, da Rosa MI, Bozzetti MC. Accuracy of CA 125 in the diagnosis of ovarian tumors: a quantitative systematic review. Eur J Obstet Gynecol Reprod Biol. 2009; 142(2): 99–105. doi: 10.1016/j.ejogrb.2008.08.011 PMID: 18995946
7. Kristjansdottir B, Levan K, Partheen K, Sundfeldt K. Diagnostic performance of the biomarkers HE4 and CA125 in type I and type II epithelial ovarian cancer. Gynecol Oncol. 2013; 131(1): 52–8. doi: 10.1016/j.ygyno.2013.07.054 PMID: 23891789
8. Partheen K, Kristjansdottir B, Sundfeldt K. Evaluation of ovarian cancer biomarkers HE4 and CA-125 in women presenting with a suspicious cystic ovarian mass. J Gynecol Oncol. 2011; 22(4): 244–52. doi: 10.3802/jgo.2011.22.4.244 PMID: 22247801
9. Moore RG, Brown AK, Miller MC, Skates S, Allard WJ, Verch T, et al. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol Oncol. 2008; 108(2): 402–8. PMID: 18961248
10. Rosen DG, Wang L, Atkinson JN, Yu Y, Lu KH, Diamandis EP, et al. Potential markers that complement expression of CA125 in epithelial ovarian cancer. Gynecol Oncol. 2005; 99(2): 267–77. PMID: 16061277
11. Sugai M, Umezu H, Yamamoto T, Jiang S, Iwami H, Tanaka T, et al. Expression of hepatocyte nuclear factor 4 alpha in primary ovarian mucinous tumors. Pathol Int. 2008; 58(11): 681–6. doi: 10.1111/j.1440-1827.2008.02293.x PMID: 18844932
12. Giuntoli RL 2nd, Rodriguez GC, Whitaker RS, Dodge R, Voynow JA. Mucin gene expression in ovarian cancers. Cancer Res. 1998; 58(23): 5546–50. PMID: 9850092
13. Lau SK, Weiss LM, Chu PG. Differential expression of MUC1, MUC2, and MUC5AC in carcinomas of various sites: an immunohistochemical study. Am J Clin Pathol. 2004; 122(1): 61–9. PMID: 15272531
14. Kufe DW. Mucins in cancer: function, prognosis and therapy. Nat Rev Cancer. 2009; 9(12): 874–85. doi: 10.1038/nrc2761 PMID: 19935676
15. Tarp MA, Clausen H. Mucin-type O-glycosylation and its potential use in drug and vaccine development. Biochim Biophys Acta. 2008; 1780(3): 546–63. PMID: 17988798
16. Bennett EP, Mandel U, Clausen H, Gerken TA, Fritz TA, Tabak LA. Control of mucin-type O-glycosylation: a classification of the polypeptide GalNAc-transferase gene family. Glycobiology. 2012; 22(6): 736–56. doi: 10.1093/glycob/cws182 PMID: 22183981
17. Byrd JC, Bresalier RS. Mucins and mucin binding proteins in colorectal cancer. Cancer Metastasis Rev. 2004; 23(1–2): 77–99. PMID: 15197326
18. Remmers N, Anderson JM, Linde EM, DiMaio DJ, Lazenby AJ, Wandall HH, et al. Aberrant expression of mucin core proteins and O-linked glycans associated with progression of pancreatic cancer. Clin Cancer Res. 2013; 19(8): 2016–2024. doi: 10.1158/1078-0432.CCR-12-2662 PMID: 23446987
19. Kristjansdottir B, Partheen K, Fung ET, Marcickiewicz J, Yip C, Brannstrom M, et al. O-linked glycosylation and its potential use in drug and vaccine development. Biochim Biophys Acta. 2008; 1780(3): 546–63. PMID: 17988798
20. Koda Y, Soejima M, Kimura H. The polymorphisms of fucosyltransferases. Leg Med (Tokyo). 2001; 3(1): 2–14. PMID: 12935727
21. Le Pendu J, Marionneau S, Cailleau-Thomas A, Rocher J, Le Moullac-Vaidye B, Clement M, ABH and Lewis histo-blood group antigens in cancer. APMS. 2001; 109(1): 9–31. PMID: 11297197
22. Linde S, Mahdavi J, Semino-Mora C, Olsen C, Carlstedt I, Boren T, et al. Role of ABO secretor status in mucosal innate immunity and H. pylori infection. PLoS Pathog. 2008; 4(1): e2. doi: 10.1371/journal.ppat.0040002 PMID: 18179282
23. Jin C, Ekwall AK, Bylund J, Bjorkman L, Estrella RP, Whitelock JM, et al. Human synovial lubricin expresses sialyl Lewis x determinant and has L-selectin ligand activity. J Biol Chem. 2012; 287(43): 35922–33. doi: 10.1074/jbc.M112.363119 PMID: 22930755
24. Kristjansdottir B, Partheen K, Fung ET, Marcickiewicz J, Yip C, Brannstrom M, et al. O-linked glycosylation and its potential use in drug and vaccine development. Biochim Biophys Acta. 2008; 1780(3): 546–63. PMID: 17988798
25. Gustafsson JK, Navabi N, Rodriguez-Pineiro AM, Alomran AH, Premaratne P, Fernandez HR, et al. Dynamic changes in mucus thickness and ion secretion during Citrobacter rodentium infection and clearance. PLoS One. 2013; 8(12): e84430. doi: 10.1371/journal.pone.0084430 PMID: 24386378
Kurman RJ, Shih Ie M. The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol. 2009; 112(1): 47–54. doi: 10.1097/PAS.0b013e3181d319f6 PMID: 19007974

Welshinger M, Finstad CL, Venkatraman E, Federici MG, Rubin SC, Lewis JL Jr., et al. Expression of A, B, and H blood group antigens in epithelial ovarian cancer: relationship to tumor grade and patient survival. Gynecol Oncol. 1996; 62(1): 106–12. PMID: 8960281

Boman F, Buisine MP, Wacrenier A, Querleu D, Aubert JP, Porchet N. Mucin gene transcripts in benign and borderline mucinous tumors of the ovary: an in situ hybridization study. J Pathol. 2001; 193(3): 339–44. PMID: 11241143

Singh AP, Senapati S, Ponnusamy MP, Jain M, Lele SM, Davis JS, et al. Clinical potential of mucins in diagnosis, prognosis, and therapy of ovarian cancer. Lancet Oncol. 2008; 9(11): 1076–85. doi: 10.1016/S1470-2045(08)70277-8 PMID: 19012856

Feng H, Ghazizadeh M, Konishi H, Araki T. Expression of MUC1 and MUC2 mucin gene products in human ovarian carcinomas. Jpn J Clin Oncol. 2002; 32(12): 525–9. PMID: 12578901

Chauhan SC, Kumar D, Jaggi M. Mucins in ovarian cancer diagnosis and therapy. J Ovarian Res. 2009; 2: 21. doi: 10.1186/1757-2215-2-21 PMID: 20034397

Rossez Y, Maes E, Lefebvre Darroman T, Gosset P, Ecobichon C, Joncquel Chevalier Curt M, et al. Almost all human gastric mucin O-glycans harbor blood group A, B or H antigens and are potential binding sites for Helicobacter pylori. Glycobiology. 2012; 22(9): 1193–206. doi: 10.1093/glycob/cws072 PMID: 22522599

Wilson NL, Schulz BL, Karlsson NG, Packer NH. Sequential analysis of N- and O-linked glycosylation of 2D-PAGE separated glycoproteins. J Proteome Res. 2002; 1(6): 521–9. PMID: 12645620

Dube DH, Bertozzi CR. Glycans in cancer and inflammation—potential for therapeutics and diagnostics. Nat Rev Drug Discov. 2005; 4(6): 477–88. PMID: 15931257

Matsumoto H, Muramatsu H, Shimotakahara T, Yanagi M, Nishijima H, Mitani N, et al. Correlation of expression of ABH blood group carbohydrate antigens with metastatic potential in human lung carcinomas. Cancer. 1993; 72(1): 75–81. PMID: 8508432

Vowden P, Lowe AD, Lennox ES, Bleehen NM. The expression of ABH and Y blood group antigens in benign and malignant breast tissue: the preservation of the H and Y antigens in malignant epithelium. Br J Cancer. 1986; 53(3): 313–9. PMID: 3516191

Cordon-Cardo C, Lloyd KO, Sakamoto J, McGroarty ME, Old LJ, Melamed MR. Immunohistologic expression of blood-group antigens in normal human gastrointestinal tract and colonic carcinoma. Int J Cancer. 1986; 37(5): 667–76. PMID: 3516890

Schoentag R, Primus FJ, Kuhns W. ABH and Lewis blood group expression in colorectal carcinoma. Cancer Res. 1987; 47(6): 1695–700. PMID: 3815366

Federici MF, Kudryashov V, Saigo PE, Finstad CL, Lloyd KO. Selection of carbohydrate antigens in human epithelial ovarian cancers as targets for immunotherapy: serous and mucinous tumors exhibit distinctive patterns of expression. Int J Cancer. 1999; 81(2): 193–8. PMID: 10188718

Yin BW, Finstad CL, Graubner K, Federici MG, Welshinger M, Kudryashov V, et al. Serological and immunohistochemical analysis of Lewis y (Ley) blood group antigen expression in epithelial ovarian cancer. Int J Cancer. 1996; 65(4): 406–12. PMID: 8621218

Zhuang H, Gao J, Hu Z, Liu J, Liu D, Lin B. Co-expression of Lewis y antigen with human epidermidis protein 4 in ovarian epithelial carcinoma. PLoS One. 2013; 8(7): e68994. doi: 10.1371/journal.pone.0068994 PMID: 23894390

Wamunyokoli FW, Bonome T, Lee JY, Feltmate CM, Welch WR, Radonovich M, et al. Expression profiling of mucinous tumors of the ovary identifies genes of clinicopathologic importance. Clin Cancer Res 2006; 12(3 Pt 1): 690–700. PMID: 16467078

Kurman RJ, Shih Ie M. The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol. 2010; 34(3): 433–43. doi: 10.1097/PAS.0b013e3181d319f6 PMID: 20154587

Vaughan S, Coward JI, Berchuck A, Berek JS, Brenton JD, et al. Rethinking ovarian cancer: recommendations for improving outcomes. Nat Rev Cancer. 2011; 11(10): 719–25. doi: 10.1038/nrc3144 PMID: 21941283

Hess V, A’Hern R, Nasiri N, King DM, Blake PR, Barton DP, et al. Mucin expression in ovarian cancer: a separate entity requiring specific treatment. J Clin Oncol. 2004; 22(6): 1040–4. PMID: 15020606

Kelemen LE, Kobel M. Mucinous carcinomas of the ovary and colorectum: different organ, same dilemma. Lancet Oncol. 2011; 12(11): 1071–80. doi: 10.1016/S1470-2045(11)70058-4 PMID: 21616717

Wongkham S, Sheehan JK, Boonla C, Patrakittkomjom S, Howard M, Kirkham S, et al. Serum MUC5AC mucin as a potential marker for cholangiocarcinoma. Cancer Letters. 2003; 195(1): 93–9. PMID: 12787517